Erratum: Development of an effective therapy for chronic myelogenous leukemia (Cancer Journal (United States) (2011) 17 (477Y486) DOI: 10.1097/PPO.0b013e318237e5b7);Development of an effective therapy for chronic myelogenous leukemia

Cancer Journal

Volumn 17, Issue 6, 2011, Pages 477-486

  Woessner, David W ^a   Lim, Carol S ^a   Deininger, Michael W ^b,c  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c NONE   (United States)

Author keywords

BCR ABL; Chronic myeloid leukemia; drug resistance; synthetic lethality; tyrosine kinase inhibitors

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; AP 234664; ARSENIC TRIOXIDE; BAFETINIB; BCR ABL PROTEIN; BMS 833923; BOSUTINIB; CYTARABINE; DANUSERTIB; DASATINIB; DCC 2036; GELDANAMYCIN; GM K562; HG 7 85 01; IMATINIB; INTERFERON; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; NILOTINIB; ONO 12380; PF 04449913; PONATINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; QLT 0267; SARACATINIB; SGX 393; TALL 104; TANESPIMYCIN; TOZASERTIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; VORINOSTAT; XL 228; ZILEUTON; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; BLOOD TOXICITY; CHRONIC MYELOID LEUKEMIA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDICATION; HUMAN; LETHALITY; LOW DRUG DOSE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

EID: 83755178897     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/01.PPO.0000439100.07392.95     Document Type: Erratum

References (124)

1. Kantarjian H, O'Brien S, Jabbour E, et al. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol. 2011;29:3173-3178.
2. Signorovitch JE, Wu EQ, Betts KA, et al. Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. Curr Med Res Opin. 2011;27:1263-1271.
3. Tauchi T, Kizaki M, Okamoto S, et al. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res. 2011;35: 585-590.
4. Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983;306:277-280. (Pubitemid 14232360)
5. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290-293.
6. Anafi M, Gazit A, Gilon C, et al. Selective interactions of transforming and normal abl proteins with ATP, tyrosineYcopolymer substrates, and tyrphostins. J Biol Chem. 1992;267:4518-4523.
7. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037. (Pubitemid 32267972)
8. National Cancer Institute, National Institutes of Health. Surveillance Epidemiology and End Results Web site. Available at: http:// seer.cancer.gov/statfacts/html/cmyl.html. Accessed July 14, 2011.
9. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100: 2292-2302.
10. Wite LJ, Blackburn EK, Callender ST, et al. Chronic granulocytic leukaemia: comparison of radiotherapy and busulphan therapy. Report of the Medical Research Council's working party for therapeutic trials in leukaemia. Br Med J. 1968;1:201-208.
11. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood. 1993;82:398-407. (Pubitemid 23206102)
12. Rushing D, Goldman A, Gibbs G, et al. Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia. Am J Clin Oncol. 1982;5:307-313. (Pubitemid 12058972)
13. Richards SM. Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta-analysis of three randomized trials. Chronic myeloid leukemia trialists' collaborative group. Br J Haematol. 2000;110:573-576.
14. Pavlu J, Szydlo RM, Goldman JM, et al. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood. 2011;117:755-763.
15. Breccia M, Palandri F, Iori AP, et al. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. Leuk Res. 2010;34: 143-147.
16. Oyekunle A, Klyuchnikov E, Ocheni S, et al. Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Acta Haematol. 2011;126:30-39.
17. Venepalli N, Rezvani K, Mielke S, et al. Role of allo-SCT for CML in 2010. Bone Marrow Transplant. 2010;45:1579-1586.
18. Talpaz M, Kantarjian HM, McCredie K, et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.NEngl JMed. 1986;314:1065-1069. (Pubitemid 16137079)
19. Dowding C, Gordon M, Guo AP, et al. Potential mechanisms of action of interferon-alpha in CML. Leuk Lymphoma. 1993;11(1 suppl):185-191. (Pubitemid 23274157)
20. Guilhot F, Lacotte-Thierry L. Interferon-alpha: mechanisms of action in chronic myelogenous leukemia in chronic phase. Hematol Cell Ther. 1998;40:237-239. (Pubitemid 28500732)
21. Ohnishi K, Ohno R, Tomonaga M, et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood. 1995;86:906-916.
22. Tura S, Baccarani M, Zuffa E, et al. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330:820-825. (Pubitemid 24083561)
23. Beck JR, Guilhot J, Giles FJ, et al. Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia. Leuk Lymphoma. 2001;41:117-124. (Pubitemid 32294195)
24. Silver RT,Woolf SH, Hehlmann R, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood. 1999;94:1517-1536. (Pubitemid 29411301)
25. Silberman G, Crosse MG, Peterson EA, et al. Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries. N Engl J Med. 1994;331:1063-1067. (Pubitemid 24317700)
26. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260-2270.
27. Nicolini FE, Turkina A, Shen ZX, et al. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosomeYpositive chronic myeloid leukemia in the chronic phase. Cancer. 2011.
28. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronicmyeloid leukemia. N Engl JMed. 2010;362:2251-2259.
29. Deininger M, O'Brien SG, Guilhot F, et al. International Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. ASH Annual Meeting Abstracts. 2009;114:1126.
30. Corm S, Micol J, Leroyer A, et al. Kinetic of chronic myeloid leukaemia (CML) prevalence in Northern France since the introduction of imatinib. J Clin Oncol. 2008;26(20 suppl):Abstract 7088.
31. Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCRABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma. 2008;49:615-619. (Pubitemid 351517198)
32. Baccarani M, Castagnetti F, Gugliotta G, et al. Response definitions and European Leukemianet Management recommendations. Best Pract Res Clin Haematol. 2009;22:331-341.
33. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-1432. (Pubitemid 37211057)
34. Radich JP. Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia. Cancer. [published online ahead of print June 29, 2011] doi:10.1002/cncr.26280.
35. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105:3-7. (Pubitemid 30036380)
36. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
37. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99: 1928-1937. (Pubitemid 34525471)
38. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-3539. (Pubitemid 34534519)
39. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652. (Pubitemid 34815868)
40. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004. (Pubitemid 36302244)
41. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417. (Pubitemid 44903745)
42. Cortes JE, BaccaraniM, Guilhot F, et al. Phase III, randomized, openlabel study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010;28:424-430.
43. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041-6051.
44. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6- methylphenyl)- 2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47:6658-6661. (Pubitemid 40053752)
45. Lindauer M, Hochhaus A. Dasatinib. Recent results. Cancer Res. 2010;184:83-102.
46. BurgessMR, Skaggs BJ, Shah NP, et al. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformationspecific binding in resistance. Proc Natl Acad Sci U S A. 2005;102: 3395-3400. (Pubitemid 40328056)
47. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosomeYpositive leukemias. N Engl J Med. 2006;354: 2531-2541. (Pubitemid 43882349)
48. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109: 2303-2309. (Pubitemid 46425867)
49. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinibresistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007;109:4143-4150. (Pubitemid 46743375)
50. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007; 109:3207-3213. (Pubitemid 46572505)
51. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26:3204-3212.
52. Porkka K, Khoury HJ, Paquette RL, et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010;116:377-386.
53. Apperley JF, Cortes JE, Kim DW, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: mthe START a trial. J Clin Oncol. 2009;27:3472-3479.
54. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129-141. (Pubitemid 40248339)
55. Weisberg E, Manley P, Mestan J, et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006;94:1765-1769. (Pubitemid 43882564)
56. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosomeYpositive ALL. N Engl J Med. 2006;354:2542-2551. (Pubitemid 43882350)
57. le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008;111:1834-1839. (Pubitemid 351451490)
58. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosomeYpositive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540-3546. (Pubitemid 350159618)
59. Koren-Michowitz M, le Coutre P, Duyster J, et al. Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant. Cancer. 2010;116:4564-4572.
60. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16:2190-2196. (Pubitemid 35331833)
61. Gromicho M, Dinis J, Magalhaes M, et al. Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1. Leuk Lymphoma. 2011;52: 1980-1990.
62. Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl- N-nitrosourea (ENU)Ybased mutagenesis screen: high efficacy of drug combinations. Blood. 2006;108:2332-2338. (Pubitemid 44497517)
63. von Bubnoff N, Manley PW, Mestan J, et al. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood. 2006;108:1328-1333. (Pubitemid 44232032)
64. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007;110:2242-2249.
65. Laneuville P, Dilea C, Yin OQ, et al. Comparative in vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia. J Clin Oncol. 2010;28:e169-e171; author reply e72.
66. Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008;112:3330-3338.
67. Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol. 2009;27:4204-4210.
68. Burke AC, Swords RT, Kelly K, et al. Current status of agents active against the T315I chronic myeloid leukemia phenotype. Expert Opin Emerg Drugs. 2011;16:85-103.
69. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029-1035.
70. Deininger M. Hematology: curing CML with imatinibVa dream come true? Nat Rev Clin Oncol. 2011;8:127-128.
71. Corbin AS, Agarwal A, Loriaux M, et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121:396-409.
72. Giles FJ, Rosti G, Beris P, et al. Nilotinib is superior to imatinib as firstline therapy of chronic myeloid leukemia: the ENESTnd study. Expert Rev Hematol. 2010;3:665-673.
73. Mauro MJ, Deininger MW. Management of drug toxicities in chronic myeloid leukaemia. Best Pract Res Clin Haematol. 2009;22:409-429.
74. Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103:553-561.
75. Boschelli DH, Ye F,Wang YD, et al. Optimization of 4-phenylamino-3- quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem. 2001;44:3965-3977. (Pubitemid 33051486)
76. Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr- Abl+ neoplastic cells. Cancer Res. 2006;66:11314-11322. (Pubitemid 46009962)
77. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2009;27:469-471.
78. Huang WS, Metcalf CA, Sundaramoorthi R, et al. Discovery of 3-[2- (imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpipera zin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem. 2010;53:4701-4719.
79. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009; 16:401-412.
80. Gozgit JM, Wong MJ, Wardwell S, et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther. 2011;10:1028-1035.
81. Cortes J, Talpaz M, Bixby D, et al. A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings. ASH Annual Meeting Abstracts. 2010;116:210.
82. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol. 2003;4:842-854. (Pubitemid 37411723)
83. Howard S, Berdini V, Boulstridge JA, et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem. 2009;52:379-388.
84. Tanaka R, Squires MS, Kimura S, et al. Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABLYpositive leukemic cells. Blood. 2010;116:2089-2095.
85. Balabanov S, Gontarewicz A, Keller G, et al. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multikinase inhibitor Danusertib in BCR-ABLYpositive cells in vitro. PLoS One. 2011;6:e19164.
86. Vertex's Collaborator Merck Suspends Patient Enrollment in Clinical Trials of MK-0457 (VX-680) Pending Full Analysis of Clinical Data. 2007. Available at: www.drugs.com/clinical-trials/vertex-s-collaboratormerck-suspends- patient-enrollment-clinical-trials-mk-0457-vx-680- pending-full-2764.html. Accessed July 31, 2011.
87. Chan WW, Wise SC, Kaufman MD, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell. 2011;19:556-568.
88. Adrian FJ, Ding Q, Sim T, et al. Allosteric inhibitors of Bcr-AblY dependent cell proliferation. Nat Chem Biol. 2006;2:95-102.
89. Deng X, Okram B, Ding Q, et al. Expanding the diversity of allosteric bcr-abl inhibitors. J Med Chem. 2010;53:6934-6946.
90. Zhang J, Adrian FJ, Jahnke W, et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010;463:501-506.
91. Iacob RE, Zhang J, Gray NS, et al. Allosteric interactions between the myristate- and ATP-site of the Abl kinase. PLoS One. 2011;6:e15929.
92. McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol. 1993;13:7587-7595. (Pubitemid 23354283)
93. Zhao X, Ghaffari S, Lodish H, et al. Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat Struct Biol. 2002;9:117-120.
94. Beissert T, Puccetti E, Bianchini A, et al. Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571. Blood. 2003;102:2985-2993. (Pubitemid 37248874)
95. Dixon AS, Pendley SS, Bruno BJ, et al. Disruption of Bcr-Abl coiled coil oligomerization by design. J Biol Chem. 2011;286:27751-27760.
96. Zhang H, Trachootham D, Lu W, et al. Effective killing of Gleevecresistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia. 2008;22:1191-1199. (Pubitemid 351833787)
97. Sun H, Kapuria V, Peterson LF, et al. Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Blood. 2011;117:3151-3162.
98. Gorre ME, Ellwood-Yen K, Chiosis G, et al. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood. 2002;100:3041-3044.
99. Isaacs JS, XuW, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell. 2003;3:213-217. (Pubitemid 37443877)
100. Tsukahara F, Maru Y. Bag1 directly routes immature BCR-ABL for proteasomal degradation. Blood. 2010;116:3582-3592.
101. Burchert A, Wolfl S, Schmidt M, et al. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood. 2003;101:259-264. (Pubitemid 36025916)
102. Bocchia M, Gentili S, Abruzzese E, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet. 2005;365:657-662. (Pubitemid 40260886)
103. Cathcart K, Pinilla-Ibarz J, Korontsvit T, et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood. 2004;103:1037-1042. (Pubitemid 38129569)
104. Telegeev GD, Dubrovska AN, Nadgorna VA, et al. Immunocytochemical study of Bcr and Bcr-Abl localization in K562 cells. Exp Oncol. 2010;32: 81-83.
105. Van Denderen J, Hermans A, Meeuwsen T, et al. Antibody recognition of the tumor-specific Bcr-Abl joining region in chronic myeloid leukemia. J Exp Med. 1989;169:87-98. (Pubitemid 19035544)
106. Perez-Martinez D, Tanaka T, Rabbitts TH. Intracellular antibodies and cancer: new technologies offer therapeutic opportunities. Bioessays. 2010;32:589-598.
107. Tse E, Lobato MN, Forster A, et al. Intracellular antibody capture technology: application to selection of intracellular antibodies recognizing the BCR-ABL oncogenic protein. J Mol Biol. 2002;317: 85-94. (Pubitemid 34722201)
108. Wojcik J, Hantschel O, Grebien F, et al. A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain. Nat Struct Mol Biol. 2010;17:519-527.
109. Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol. 2011;29:591-599.
110. Zhao C, Chen A, Jamieson CH, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature. 2009;458:776-779.
111. Irvine DA, Zhang B, Allan EK, et al. Combination of the hedgehog pathway inhibitor LDE225 and nilotinib eliminates chronic myeloid leukemia stem and progenitor cells. American Society of Hematology Annual Meeting; December 5, 2009: New Orleans, LA.
112. Sheridan C. Genentech obtains proof of concept for hedgehog inhibition. Nat Biotech. 2009;27:968-969.
113. Zhao C, Blum J, Chen A, et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 2007; 12:528-541. (Pubitemid 350199070)
114. Naka K, Hoshii T, Muraguchi T, et al. TGF-betaYFOXO signaling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010;463:676-680.
115. Jin L, Tabe Y, Konoplev S, et al. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther. 2008;7:48-58.
116. Gregory MA, Phang TL, Neviani P, et al. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell. 2010;18:74-87.
117. Bellodi C, Lidonnici MR, Hamilton A, et al. Targeting autophagy potentiates tyrosine kinase inhibitorYinduced cell death in Philadelphia chromosomeYpositive cells, including primary CML stem cells. J Clin Invest. 2009;119:1109-1123.
118. Brossart P, Schneider A, Dill P, et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1- specific cytotoxic T-lymphocytes. Cancer Res. 2001;61:6846-6850. (Pubitemid 32896509)
119. Chen Y, Hu Y, Zhang H, et al. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet. 2009;41:783-792.
120. Mancini M, Corradi V, Petta S, et al. mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein. Leuk Res. 2010;34:641-648.
121. Warsch W, Kollmann K, Eckelhart E, et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 2011;117:3409-3420.
122. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7:441-453. (Pubitemid 46823444)
123. Nelson EA, Walker SR, Weisberg E, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011;117:3421-3429.
124. Melo JV, Goldman JM, Deininger M. Signal transduction inhibitors in chronic myeloid leukemia. In: Myeloproliferative Disorders. Berlin, Germany: Springer; 2007:75-102.